Valencia Technologies Secures Strategic Investment of $35 Million from Brooks Advisory Group, Appoints James D. Surek as CEO
Valencia will seek to leverage the investment as well as Surek’s leadership experience to drive commercialization of its flagship eCoin system to develop minimally invasive treatments for urinary incontinence.
Image Credit: Adobe Stock Images/Tom
Valencia Technologies, a neuromodulation company specializing in minimally invasive treatments for urinary incontinence, has secured a strategic investment of up to $35 million from Brooks Advisory Group. Additionally, the company announced the appointment of James D. Surek as its new CEO. Moving forward, Valencia said that it will take advantage of the investment and Surek’s experience in commercial leadership to drive commercialization of its flagship eCoin system.1
"We are excited to help Valencia Technologies accelerate and scale commercialization of eCoin and continue to carry forward the vision of Jeff Greiner to transform the standard of care for bladder dysfunction," said Dain Black, managing partner, BMG, in a press release.
Prior to joining Valencia, Surek played a key role in Advanced Bionics’ $3 billion acquisition by Boston Scientific and leading Entellus Medical’s revenue growth from under $1 million to over $70 million.1
"I am excited to return to the neuromodulation space," said Surek, in the press release. “"Many physicians and patients have already experienced the benefits of Valencia's game-changing technology. We are looking forward to expanding our footprint in the market to bring our solution to those who want or require another option.”
According to Valencia, the eCoin system is a coin-sized neurostimulator implanted near the ankle to treat urgent urinary incontinence (UUI). The device provides stimulation to the tibial nerve twice a week and is implanted under skin near the ankle in a minimally invasive procedure.
eCoin was evaluated in a prospective, multicenter, single-arm trial that consisted of 137 patients with refractory UUI. The dual primary endpoints of the study were the proportion of subjects who achieved at least 50% reduction from baseline and safety measures associated with device-related adverse events (AEs). During the study, investigators collected a questionnaire centered around overactive bladder, Patient Global Impression of Improvement, custom Likert scale on subject satisfaction, and a 3-day voiding diary.2
The results from the study show that eCoin reduced UUI episodes by at least 50% in 78% of patients. Additionally, 48% experienced at least a 75% reduction, with 22% on a three-day diary. No major AEs were reported.1,2
"Many patients suffering from the embarrassment and anxiety of living with overactive bladder want an alternative to costly medications and other more involved treatments. With the eCoin system, I can offer urge urinary incontinence patients an effective alternative with a single procedure, few office visits, and 'set it and forget it' convenience,” said Jason Kim, MD, Stony Brook Medicine, in the press release.
According to a study published in Climacteric, prior research indicates that the prevalence of urinary incontinence (UI) ranges from approximately 5% to 70%, with a majority reporting a prevalence between 25% and 45%, which increases with aging. Data shows that in women over 70 years of age, 40% of the global population are living with some form of UI. In nursing homes, these rates have been found to be considerably higher. Prevalence has ranged from 1.8% to 30.5% in European populations, from 1.5% to 15.2% in Asian populations, and from 1.7% to 36.4% in US populations. The EPIC study estimated that the global prevalence of UI was 8.7%.
Despite the high prevalence, life expectancy has increased in recent years. However, prevalence is expected to increase moving forward, meaning that there will be an increased need for UI treatments.3
References
1. Valencia Technologies Announces Strategic Investment of up to $35 Million and Appointment of James D. Surek as Chief Executive Officer. PR Newswire. February 20, 2025. Accessed February 20, 2025. https://www.prnewswire.com/news-releases/valencia-technologies-announces-strategic-investment-of-up-to-35-million-and-appointment-of-james-d-surek-as-chief-executive-officer-302380890.html
2. Two-year Pivotal Study Analysis of the Safety and Efficacy of Implantable Tibial Nerve Stimulation With eCoin® for Urgency Urinary Incontinence. ScienceDirect. Accessed February 20, 2025. https://www.sciencedirect.com/science/article/abs/pii/S0090429524006307
3. The prevalence of urinary incontinence. Taylor & Francis. December 21, 2018. Accessed February 20, 2025. https://www.tandfonline.com/doi/full/10.1080/13697137.2018.1543263#abstract
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
Novo Nordisk, The United Laboratories Ink Exclusive License Agreement for Triple Receptor Agonist
March 25th 2025Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of China for obesity and type 2 diabetes for an upfront payment of $200 million.
Sanofi Bolsters Immunology Pipeline with Acquisition of Dren Bio’s DR-0201 for Up to $1.9 Billion
March 20th 2025DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing promise in treating refractory B-cell-mediated autoimmune diseases.
